Quote on Pharma Sector Outlook By Yadhu Ramachandran, Geojit Financial Services
Below Quote on Pharma Sector Outlook By Yadhu Ramachandran, Research analyst at Geojit Financial Services
The recent rise in the pharma stocks can be attributed to a number of factors, such as an increase in COVID-19 cases in India, a price increase of up to 12% for essential medicines beginning Apr 01st as approved by the NPPA (National Pharmaceutical Pricing Authority), and a moderation in raw material prices due to an improvement in supply from China. Hence, companies with strong domestic exposure are likely to perform well. Export-oriented pharma companies have a modest outlook as the price pressure on US generics is expected to continue in FY24; however, the moderation in raw material costs and valuation will help to attain steady performance even in a volatile market.
Tag News
We anticipate immense potential benefits from the upcoming Sovereign Gold Bond Tranche in FY...